Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DMF73Z
|
|||
| Drug Name |
DKN-01
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Biliary tract cancer [ICD-11: 2C17; ICD-10: C24.9] | Phase 2 | [1] | |
| Endometrial cancer [ICD-11: 2C76; ICD-9: 182] | Phase 2 | [2] | ||
| Esophageal cancer [ICD-11: 2B70; ICD-9: 150] | Phase 2 | [1] | ||
| Ovarian cancer [ICD-11: 2C73; ICD-10: C56; ICD-9: 183] | Phase 2 | [2] | ||
| Cholangiocarcinoma [ICD-11: 2C12.10; ICD-10: C22.1] | Phase 1/2 | [3] | ||
| Multiple myeloma [ICD-11: 2A83; ICD-10: C90.0] | Phase 1/2 | [4] | ||
| Oesophagogastric junction cancer [ICD-11: 2B71.Z] | Phase 1/2 | [2] | ||
| Prostate cancer [ICD-11: 2C82.0; ICD-9: 185] | Phase 1/2 | [5] | ||
| Company |
Leap Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Dickkopf-related protein 1 (DKK1) | Target Info | Inhibitor | [6] |
| KEGG Pathway | Wnt signaling pathway | |||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| Wnt Signaling Pathway | ||||
| FSH Signaling Pathway | ||||
| Pathway Interaction Database | Presenilin action in Notch and Wnt signaling | |||
| Wnt signaling network | ||||
| Direct p53 effectors | ||||
| Regulation of nuclear beta catenin signaling and target gene transcription | ||||
| Validated targets of C-MYC transcriptional repression | ||||
| Reactome | TCF dependent signaling in response to WNT | |||
| Negative regulation of TCF-dependent signaling by WNT ligand antagonists | ||||
| WikiPathways | Mesodermal Commitment Pathway | |||
| Endoderm Differentiation | ||||
| Differentiation Pathway | ||||
| Hair Follicle Development: Cytodifferentiation (Part 3 of 3) | ||||
| Primary Focal Segmental Glomerulosclerosis FSGS | ||||
| Cardiac Progenitor Differentiation | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03818997) Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric Cancer (DYNAMIC). U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | ClinicalTrials.gov (NCT01711671) A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. U.S. National Institutes of Health. | |||
| REF 5 | ClinicalTrials.gov (NCT03837353) A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1. U.S. National Institutes of Health. | |||
| REF 6 | The anti-DKK1 antibody DKN-01 as an immunomodulatory combination partner for the treatment of cancer. Expert Opin Investig Drugs. 2020 Jul;29(7):639-644. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.